Edition:
United Kingdom

Intra-Cellular Therapies Inc (ITCI.OQ)

ITCI.OQ on NASDAQ Stock Exchange Global Select Market

19.46USD
19 Apr 2018
Change (% chg)

$-0.44 (-2.21%)
Prev Close
$19.90
Open
$19.72
Day's High
$19.91
Day's Low
$19.22
Volume
91,512
Avg. Vol
161,240
52-wk High
$25.74
52-wk Low
$7.85

Chart for

About

Intra-Cellular Therapies, Inc. (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system... (more)

Overall

Beta: 0.56
Market Cap(Mil.): $1,088.14
Shares Outstanding(Mil.): 54.68
Dividend: --
Yield (%): --

Financials

  ITCI.OQ Industry Sector
P/E (TTM): -- 200.91 33.50
EPS (TTM): -2.13 -- --
ROI: -23.66 -0.75 13.17
ROE: -23.83 -2.86 14.98

BRIEF-Intra-Cellular Therapies Announces Positive Pre-NDA Meeting With FDA For Schizophrenia Treatment

* INTRA-CELLULAR THERAPIES ANNOUNCES POSITIVE PRE-NDA MEETING WITH FDA FOR LUMATEPERONE FOR THE TREATMENT OF SCHIZOPHRENIA

13 Mar 2018

BRIEF-Intra-Cellular Therapies Reports Q4 Loss Per Share $0.56

* INTRA-CELLULAR THERAPIES REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

01 Mar 2018

BRIEF-Intra-Cellular Therapies receives FDA fast track designation for Schizophrenia treatment drug

* Intra-Cellular Therapies receives FDA fast track designation for lumateperone for the treatment of schizophrenia

20 Nov 2017

Earnings vs. Estimates